OBJECTIVES: The continuous booming of mHealth allows the development of new models of care, and might revolutionize the overall delivery of care. However, evidence on the potential effects of mHealth is still scant and current literature mostly focuses on chronic diseases. To address this research gap, we researched mHealth current utilization in cancer care and aimed at assessing the perceived impact of mHealth on clinicians and patients by comparing the opinions of those who use it with those of individuals that still do not use mHealth. METHODS: We carried out a survey on 1,033 cancer patients and 1,116 oncologists in 5 European countries (France, Germany, Italy, Spain and the UK) and the United States.The objective of the questionnaire was to assess the current State of the Art of mHealth in cancer care (how many use it and for which purposes) and the perceived mHealth performance with respect to several different dimensions:efficiency,clinical effectiveness, and quality of life. RESULTS: The proportion of Users among clinicians is higher than the one observed in the patient group (77% vs 28%).This gap takes place in all geographic areas. As to the impact of mHealth on clinicians’activities and on patients’overall quality of life, Users express a higher degree of agreement with the mHealth potential. Among Users, those who use mHealth more frequently and for symptom management and compliance enhancement express higher levels of perceived improvement. CONCLUSIONS: mHealth can provide a more accurate way of managing cancer care. Although evidence is not definitive on actual benefits, Users perceive higher levels of satisfaction with respect to efficiency, effectiveness and impact on overall quality of life. However, the actual spread of such technologies is still scarce, especially among patients, with very limited utilization for activities related to treatment and follow-up and with several barriers to be tackled,ranging from financial management to privacy concerns.